Yang Li1, Chongqing Xu1,2, Qiquan Yu1. 1. Department of Thoracic Surgery, Long Hua Hospital, Shanghai University of Traditional Chinese Medicine Shanghai, China. 2. Department of Orthopaedics, Long Hua Hospital, Shanghai University of Traditional Chinese Medicine Shanghai, China.
Abstract
OBJECTIVE: Bone tissue is the most common metastatic location besides lung and liver. 30%~40% of patients with non-small cell lung cancer (NSCLC) will have bone metastasis (BM) in the development of the disease. This study aims to explore the relevant risk factors through multivariate analysis, in order to provide basis for the prevention of BM and bone related events of NSCLC. METHODS: We analyzed 152 patients, with 67 in BM group and 85 in non-BM group. The general clinical data and laboratory indicators (mainly coagulation function) of patients were compared through univariate and multivarijate analysis. Finally, the independent risk factors of BM in patients with NSCLC were screened out. RESULTS: The results of univariate analysis show that thrombosis, clinical stage, tumor-node-metastasis (TNM) stage, prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (FIB), D-Dimer (D-D), platelet (PLT) and alkaline phosphatase (AKP) are the risk factors of BM in patients with NSCLC (p<0.05). Further multivariate logistic regression analysis suggests that the independent risk factors of BM in patients with NSCLC are clinical stage III-IV, TNM stage T1-T3, TNM stage N2-N3, FIB, APTT, D-D and AKP (P<0.05). CONCLUSION: Clinical stage III-IV, TNM stage T1-T3, TNM stage N2-N3, FIB, APTT, D-D and AKP are the independent risk factors of BM in patients with NSCLC. Meanwhile, patients with these risk factors should be screened in time, which is of great significance to prevent bone related events and relieve pain. AJTR
OBJECTIVE: Bone tissue is the most common metastatic location besides lung and liver. 30%~40% of patients with non-small cell lung cancer (NSCLC) will have bone metastasis (BM) in the development of the disease. This study aims to explore the relevant risk factors through multivariate analysis, in order to provide basis for the prevention of BM and bone related events of NSCLC. METHODS: We analyzed 152 patients, with 67 in BM group and 85 in non-BM group. The general clinical data and laboratory indicators (mainly coagulation function) of patients were compared through univariate and multivarijate analysis. Finally, the independent risk factors of BM in patients with NSCLC were screened out. RESULTS: The results of univariate analysis show that thrombosis, clinical stage, tumor-node-metastasis (TNM) stage, prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (FIB), D-Dimer (D-D), platelet (PLT) and alkaline phosphatase (AKP) are the risk factors of BM in patients with NSCLC (p<0.05). Further multivariate logistic regression analysis suggests that the independent risk factors of BM in patients with NSCLC are clinical stage III-IV, TNM stage T1-T3, TNM stage N2-N3, FIB, APTT, D-D and AKP (P<0.05). CONCLUSION: Clinical stage III-IV, TNM stage T1-T3, TNM stage N2-N3, FIB, APTT, D-D and AKP are the independent risk factors of BM in patients with NSCLC. Meanwhile, patients with these risk factors should be screened in time, which is of great significance to prevent bone related events and relieve pain. AJTR
Authors: Chad Tang; Zhongxing Liao; Kenneth Hess; William W Chance; Yan Zhuang; Garrett Jensen; Ting Xu; Ritsuko Komaki; Daniel R Gomez Journal: Acta Oncol Date: 2016-04-08 Impact factor: 4.089
Authors: Rosa Divella; Antonella Daniele; Ines Abbate; Antonia Bellizzi; Eufemia Savino; Giovanni Simone; Grazia Giannone; Francesco Giuliani; Vito Fazio; Gennaro Gadaleta-Caldarola; Cosimo Damiano Gadaleta; Ivan Lolli; Carlo Sabbà; Antonio Mazzocca Journal: Cancer Causes Control Date: 2014-08-19 Impact factor: 2.506
Authors: A K Ayan; B Erdemci; E Orsal; Z Bayraktutan; E Akpinar; A Topcu; M Turkeli; B Seven Journal: Rev Esp Med Nucl Imagen Mol Date: 2015-10-27 Impact factor: 1.359
Authors: Kian Ngiap Chua; Li Ren Kong; Wen Jing Sim; Hsien Chun Ng; Weijie Richard Ong; Jean Paul Thiery; Hung Huynh; Boon Cher Goh Journal: Oncotarget Date: 2015-10-06